Paper Details

  1. Home
  2. Paper Details

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Author: AlbrechtJ, CraxiA, DavisG L, Esteban-MurR, GordonS C, HoefsJ, LingM H, RustgiV, ShiffmanM L, TrepoC, ZeuzemS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study compared the effectiveness of interferon alone versus interferon combined with oral ribavirin in treating relapses of chronic hepatitis C infection. While interferon is the only known effective treatment for this condition, only 40% of patients respond initially, and most relapse. This study aimed to determine if adding ribavirin could improve outcomes for patients experiencing a relapse.
Paper Details　
Original Abstract of the Article :
Interferon alfa is the only effective treatment for patients with chronic hepatitis C. Forty percent of patients have an initial response to this therapy, but most subsequently relapse. We compared the effect of interferon alone with that of interferon plus oral ribavirin for relapses of chronic hep...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM199811193392102

データ提供：米国国立医学図書館（NLM）

Navigating the Labyrinth of Hepatitis C Treatment

The quest for effective treatments for chronic hepatitis C is an ongoing journey, with new therapies constantly emerging. This study delves into the world of interferon alfa-2b, a key medication for managing this viral infection, comparing its efficacy when used alone versus in combination with ribavirin.

The Impact of Ribavirin: A Key Addition to Hepatitis C Treatment

The study finds that interferon alfa-2b combined with ribavirin is more effective than interferon alone in treating relapses of chronic hepatitis C. This finding highlights the potential for combining medications to enhance treatment outcomes and improve the management of this persistent viral infection.

Optimizing Hepatitis C Treatment: A Combination Approach

This research underscores the importance of exploring combination therapies for chronic hepatitis C. The findings provide valuable guidance for healthcare providers, encouraging the use of interferon alfa-2b in combination with ribavirin for improved treatment outcomes.

Dr. Camel's Conclusion

This study sheds light on the potential for combining medications to enhance treatment outcomes for chronic hepatitis C. It highlights the importance of ongoing research to refine treatment strategies for this challenging viral infection. The findings are a reminder that the quest for effective therapies for hepatitis C is a continuous process, with new approaches constantly emerging.

Date :
  1. Date Completed 1998-11-19
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

9819447

DOI: Digital Object Identifier

10.1056/NEJM199811193392102

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.